Overview

Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide ganciclovir on a compassionate use basis to immunocompromised patients with serious cytomegalovirus (CMV) infections and to study safety and efficacy in this patient population.
Phase:
N/A
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Ganciclovir
Ganciclovir triphosphate